Functional pituitary adenomas require pharmacotherapy either as primary treatment, as surgical adjunct, or for persistent or recurrent disease. Each adenoma type has a distinct hormonal driver and a corresponding pharmacological target. Prolactinomas are the most common functional adenomas and are uniquely amenable to dopamine agonist therapy, which reduces prolactin secretion and tumor volume through a direct pituitary mechanism. Growth hormone-secreting adenomas primarily require surgery, with somatostatin analogs and pegvisomant for residual disease, as covered in Hypothal-03; dopamine agonists play a minor adjunctive role. Corticotroph adenomas causing Cushing disease are the most pharmacologically complex: because pituitary-directed drugs achieve modest and incomplete control in most patients, adrenal-directed steroidogenesis inhibitors and glucocorticoid receptor blockers are essential tools in clinical management. This module covers the full pharmacology of dopamine agonists for prolactinoma and their adjunctive use in acromegaly, and then provides a comprehensive treatment of the adrenal-targeted and pituitary-targeted agents used in Cushing disease, including ketoconazole, metyrapone, osilodrostat, mitotane, pasireotide, and mifepristone.
Prolactinomas account for approximately 40% of all pituitary adenomas and are the most common cause of non-physiological hyperprolactinemia in adults. Prolactin secretion from pituitary lactotrophs is tonically suppressed by hypothalamic dopamine, which reaches lactotrophs via the hypothalamo-hypophyseal portal circulation and activates dopamine D2R (D2 receptor subtype 2) receptors. D2R is a seven-transmembrane Gi-coupled receptor; dopamine binding reduces adenylyl cyclase activity, decreases intracellular cyclic AMP (cAMP), and inhibits prolactin gene transcription, prolactin synthesis, and prolactin secretion. In prolactinoma, lactotroph adenoma cells retain D2R expression in most cases, enabling dopamine agonists to recapitulate the tonic inhibitory signal that is lost due to portal vascular compression from the tumor mass itself. Beyond suppressing prolactin secretion, dopamine agonists produce direct antiproliferative effects on lactotroph adenoma cells: sustained D2R activation reduces tumor cell mitotic activity and promotes cellular condensation of the cytoplasm, leading to measurable tumor volume reduction in 80 to 90% of patients and normalization of tumor size in many cases.1
The clinical goals of dopamine agonist therapy in prolactinoma are fourfold: normalization of serum prolactin, restoration of gonadal function (resumption of menses and restoration of fertility in women; recovery of testosterone and sexual function in men), tumor volume reduction to relieve mass effect on adjacent structures (optic chiasm, cavernous sinus, pituitary stalk), and prevention of hypogonadism-related bone loss. In microadenomas (diameter below 10 mm), dopamine agonist monotherapy achieves prolactin normalization in 85 to 95% of patients and is curative in a subset who sustain remission after drug withdrawal. Macroprolactinomas (diameter 10 mm or above) respond similarly in terms of prolactin lowering but require longer treatment durations, and cure after drug withdrawal is less common. Surgical resection is reserved for patients who are intolerant of or resistant to dopamine agonists, or who have apoplexy requiring acute decompression. The timing and feasibility of drug withdrawal after sustained normoprolactinemia is an important clinical consideration discussed in relation to cabergoline therapy in Section 2.12
Dopamine agonist resistance, defined as failure to normalize prolactin or achieve at least 50% tumor volume reduction at maximally tolerated doses, occurs in approximately 10 to 15% of patients receiving cabergoline and in a higher proportion receiving bromocriptine. Resistance is more common with larger and more invasive tumors and with tumors that have reduced D2R expression. In resistant prolactinomas, the D2R gene is often intact but receptor protein expression is reduced, suggesting post-transcriptional or epigenetic regulation. Partial resistance may respond to dose escalation within the tolerated range; complete resistance typically necessitates surgery or, for secretory control without surgical cure, temozolomide (an alkylating agent used for aggressive or malignant pituitary adenomas).2
In patients with very large macroprolactinomas, standard immunometric prolactin assays can give falsely low or even normal values due to the hook effect: extremely high prolactin concentrations saturate both capture and detection antibodies, preventing signal formation. This can mislead the clinician into attributing a large non-functioning-appearing pituitary tumor to a different etiology. Clinical rule: whenever a large pituitary mass is found with prolactin in the normal-high or minimally elevated range, request a serial dilution (1:100) of the serum to unmask true prolactin concentration. Values that normalize or fall further on dilution confirm the hook effect and indicate a macroprolactinoma requiring dopamine agonist therapy.
Cabergoline is an ergot-derived D2R (dopamine receptor subtype 2) agonist with significantly higher D2R affinity and selectivity than bromocriptine, a longer elimination half-life (approximately 63 to 68 hours), and substantially better tolerability. The extended half-life allows twice-weekly oral dosing, typically starting at 0.25 mg twice weekly and titrating upward by 0.25 to 0.5 mg increments every 4 weeks based on serum prolactin response, with a usual effective dose range of 0.5 to 2 mg per week (most patients achieve normoprolactinemia at 1 mg per week or less). Cabergoline is absorbed from the gastrointestinal tract with peak plasma concentrations at 2 to 3 hours; it undergoes extensive first-pass hepatic metabolism, primarily via CYP3A4 (cytochrome P450 3A4) oxidation and hydrolysis, producing largely inactive metabolites excreted in feces. Drug interactions are modest: strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics) can increase cabergoline plasma levels, and dopamine antagonists (antipsychotics, metoclopramide) pharmacodynamically oppose its prolactin-lowering effect. Prolactin normalization rates with cabergoline reach 85 to 95% for microadenomas and 70 to 85% for macroprolactinomas in clinical series.3
The most important long-term safety consideration for cabergoline is cardiac valvulopathy, specifically fibrotic thickening of cardiac valve leaflets (predominantly tricuspid and mitral) with regurgitation, first described in patients with Parkinson disease receiving high cumulative doses (often 3 to 6 mg per day, dramatically higher than prolactinoma doses). The cabergoline doses used in prolactinoma treatment (typically 0.5 to 3.5 mg per week) are substantially lower than Parkinson disease doses, and large clinical series have not demonstrated a significantly elevated risk of clinically significant valve disease at these doses compared with the general population. However, European guidelines recommend baseline echocardiography before starting cabergoline for prolactinoma and periodic surveillance, particularly when doses exceed 2 mg per week or cumulative exposure is large. The valvulopathy risk is mediated by cabergoline’s agonist activity at serotonin 5-HT2B receptors on cardiac valve fibroblasts; this is a non-D2R effect that does not contribute to the therapeutic mechanism. The possibility of drug withdrawal after sustained normoprolactinemia (typically 2 years of therapy with undetectable tumor on magnetic resonance imaging (MRI)) is a clinically important management decision: approximately 65 to 70% of patients who achieve sustained normoprolactinemia on cabergoline and have no visible tumor on MRI remain normo-prolactinemic at 1 year after withdrawal.4
Bromocriptine is an older ergot dopamine agonist with a shorter half-life (approximately 6 to 8 hours), requiring twice or three times daily oral dosing, and with substantially higher rates of nausea, vomiting, orthostatic hypotension, and nasal stuffiness compared with cabergoline. Despite its inferior tolerability, bromocriptine has two important advantages that keep it in clinical use. First, bromocriptine has the longest safety record in pregnancy: it has been used for fertility treatment in hyperprolactinemic women for over four decades, with extensive reassuring data on first-trimester exposure; cabergoline, while also considered low risk in pregnancy, has a shorter and smaller safety database. Current practice in many centers is to switch women planning pregnancy from cabergoline to bromocriptine, or to discontinue dopamine agonists entirely once pregnancy is confirmed in patients with microadenomas. Second, bromocriptine is far less expensive than cabergoline in resource-limited settings. Common adverse effects of bromocriptine include nausea and vomiting (especially at initiation; mitigated by taking with food and initiating at low doses), orthostatic hypotension, headache, and digital vasospasm (Raynaud phenomenon). Rare but serious reactions include pleuropulmonary fibrosis and retroperitoneal fibrosis with long-term high-dose use.455
Candidates for cabergoline withdrawal: prolactin normalized for at least 2 consecutive years; pituitary MRI shows no visible tumor or at most minimal residual changes; no history of macroprolactinoma with significant suprasellar extension. Protocol: taper cabergoline over 2 to 4 months rather than abrupt discontinuation. Monitoring after withdrawal: prolactin at 1, 3, and 6 months, then annually. Recurrence rates: approximately 30–35% within 1 year, up to 70% at 5 years. Recurrence is managed by restarting cabergoline; response is generally preserved. Patients with macroprolactinomas or persistent radiological tumor carry higher recurrence risk and usually require indefinite therapy. Pregnancy planning complicates withdrawal timing and should be coordinated with endocrinology and obstetrics.
In acromegaly, dopamine agonists have a limited but defined pharmacological role. Growth hormone-secreting adenomas, particularly the more common granular variant, predominantly express somatostatin receptors (SSTR2 and SSTR5) rather than D2R (dopamine receptor subtype 2), so dopamine receptor agonism produces weaker suppression of growth hormone (GH) secretion than somatostatin analog (SSA) therapy. However, a subset of somatotroph adenomas co-secrete prolactin and GH from mixed lactosomatotroph tumors, and these tumors express D2R at levels sufficient to respond to cabergoline. Cabergoline monotherapy achieves insulin-like growth factor-1 (IGF-1) normalization in approximately 10 to 15% of acromegaly patients overall6 but in a higher proportion of those with elevated prolactin or with IGF-1 levels mildly above the upper limit of normal (within 1.5 times the upper limit). Cabergoline is most useful as an add-on to SSA therapy in patients with inadequate IGF-1 control on maximum SSA doses, particularly when the serum prolactin is elevated, because elevated prolactin suggests D2R expression and thus a higher likelihood of dopaminergic response. The combination of cabergoline plus SSA produces additive IGF-1 reduction in 50 to 60% of patients with partial SSA resistance.7
Pasireotide, the pan-somatostatin receptor subtype (SSTR) agonist described in Hypothal-03, is the pharmacological option when first-generation SSAs (octreotide long-acting release (LAR) or lanreotide Autogel) fail to control GH and IGF-1 in acromegaly. The pivotal PAOLA (Pasireotide versus Octreotide/Lanreotide in Acromegaly) trial demonstrated that pasireotide LAR 40 mg and 60 mg monthly produced biochemical control (normal GH and IGF-1) in 31 to 38% of patients with inadequate control on first-generation SSA, compared with 19% for switching to the alternative first-generation agent. This modest but statistically significant advantage, combined with the substantially higher hyperglycemia rate (57 to 73% on pasireotide versus 10 to 20% on first-generation SSAs), makes pasireotide a second-line choice for SSA-resistant patients in whom metabolic risk is acceptable and both GH and IGF-1 remain elevated. The decision between pasireotide, pegvisomant addition, and cabergoline addition is individualized based on the degree of biochemical uncontrol, tumor volume requirements (only SSAs reduce tumor volume), and the patient’s metabolic profile.78
Cabergoline add-on: best choice when serum prolactin is elevated (suggesting D2R expression); when IGF-1 is only mildly elevated above normal; lowest risk of new adverse effects. Pasireotide switch: choose when both GH and IGF-1 remain clearly elevated and tumor volume reduction is still needed; accept hyperglycemia management burden. Pegvisomant addition: choose when IGF-1 alone remains elevated (GH controlled), hyperglycemia risk from pasireotide is unacceptable, or maximal IGF-1 normalization is the priority; requires annual pituitary MRI (no tumor suppression). Combinations of pegvisomant plus SSA produce the highest rates of IGF-1 normalization but require monitoring for both agents.
Cushing disease results from autonomous adrenocorticotropic hormone (ACTH) hypersecretion by a corticotroph pituitary adenoma, driving bilateral adrenocortical hyperplasia and sustained cortisol excess. Unlike prolactinoma, there is no primary medical therapy for Cushing disease that matches the efficacy of surgery: transsphenoidal resection achieves biochemical remission in approximately 70 to 80% of microadenomas and 40 to 50% of macroadenomas in experienced centers, with recurrence rates of 10 to 25% at 10 years. Pharmacotherapy is therefore used in three clinical contexts: pre-surgical cortisol lowering to reduce operative risk in severe hypercortisolism; management of persistent or recurrent Cushing disease after failed or incomplete surgery; and palliation in patients who are poor surgical candidates. The drug classes available operate at four levels of the hypothalamic-pituitary-adrenal (HPA) axis: pituitary-directed agents (pasireotide, cabergoline) reduce ACTH secretion from the corticotroph; adrenal steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat, mitotane) block cortisol biosynthesis; the glucocorticoid receptor antagonist mifepristone blocks cortisol action at the tissue level; and bilateral adrenalectomy (surgical) remains an option for refractory cases.9
Pasireotide is approved for the treatment of Cushing disease and acts by suppressing ACTH secretion from corticotroph adenomas via SSTR5 (somatostatin receptor subtype 5) activation, which is the predominant somatostatin receptor subtype expressed by corticotroph tumors. In the pivotal phase 3 trial, subcutaneous (SC) pasireotide 600 mcg twice daily or 900 mcg twice daily produced urinary free cortisol (UFC) normalization in approximately 26 to 35% of patients at 6 months, with sustained responses at 12 months in a similar proportion.10 A long-acting release (LAR) formulation of pasireotide (40 mg or 60 mg intramuscular (IM) monthly) produces comparable biochemical outcomes with the convenience of monthly dosing. The high rate of pasireotide-induced hyperglycemia (occurring in over 70% of Cushing disease patients, who already carry baseline metabolic risk from cortisol excess) necessitates aggressive glucose management, predominantly with glucagon-like peptide-1 (GLP-1) receptor agonists as preferred agents, as discussed in Hypothal-03.8 The clinical response in Cushing disease is heterogeneous: predictors of better response include smaller tumor size, lower baseline UFC, and higher SSTR5 expression in tumor tissue.910
Cabergoline also suppresses ACTH in some corticotroph adenomas via D2R (dopamine receptor subtype 2) activation. Corticotroph adenomas have variable D2R expression, and published series report UFC normalization with cabergoline monotherapy in approximately 25 to 40% of patients with Cushing disease, though sustained long-term control is often incomplete or lost over time due to cabergoline resistance developing within 12 to 24 months of therapy. Cabergoline is most useful as a bridge therapy while awaiting surgery or radiation effect, or in combination with a steroidogenesis inhibitor when the latter alone does not achieve adequate control. Doses used for Cushing disease are higher than those for prolactinoma, typically 1 to 7 mg per week; the cardiac valvulopathy concern discussed in Section 2 is therefore more relevant at these elevated cumulative doses, and baseline echocardiography is recommended before starting cabergoline at doses above 2 mg per week for this indication.11
All effective treatments for Cushing disease carry a risk of adrenal insufficiency as cortisol falls from supraphysiological to normal or below-normal levels. Patients accustomed to cortisol excess may become symptomatic (fatigue, nausea, hypotension, hyponatremia) when cortisol approaches or crosses the normal range, even if biochemical values are still within the low-normal range. Teaching patients to recognize adrenal insufficiency symptoms and providing a stress-dose hydrocortisone prescription (20 mg PO at illness onset; injectable 100 mg IM or IV for vomiting or emergency) is essential at initiation of any steroidogenesis inhibitor or effective pasireotide therapy. UFC monitoring must be interpreted in the context of concurrent hydrocortisone supplementation, which suppresses the assay.
Ketoconazole is an imidazole antifungal that inhibits multiple cytochrome P450 (CYP) enzymes within the adrenal cortex, principally CYP11A1 (cholesterol side-chain cleavage enzyme), CYP11B1 (cytochrome P450 11B1, 11-beta-hydroxylase), and CYP17A1 (cytochrome P450 17A1, 17-alpha-hydroxylase/17,20-lyase), collectively reducing cortisol biosynthesis across multiple steps. The most potent inhibitory effect is at CYP17A1, which participates in both cortisol and androgen synthesis. Ketoconazole reduces urinary free cortisol (UFC) in 50 to 60% of patients with Cushing disease at doses of 400 to 1,200 mg daily in divided doses. The principal clinical liabilities are hepatotoxicity (elevated liver enzymes in up to 20% of patients; severe hepatotoxicity in up to 3%), QT interval (QT) prolongation via hERG channel inhibition, and extensive cytochrome P450 3A4 (CYP3A4) inhibition that produces numerous drug interactions: ketoconazole dramatically increases plasma concentrations of CYP3A4 substrates including cyclosporine, tacrolimus, statins, calcium channel blockers, midazolam, and many others. Ketoconazole is contraindicated in combination with QT-prolonging agents and requires liver function test (LFT) monitoring every 2 to 4 weeks during initiation and monthly thereafter. Its use in several markets has been restricted due to hepatotoxicity concerns, but it remains available and widely used in Cushing disease management.12
Metyrapone is a selective inhibitor of CYP11B1 (11-beta-hydroxylase), the enzyme that converts 11-deoxycortisol to cortisol in the zona fasciculata. Because metyrapone blocks the final step in cortisol synthesis, the upstream intermediate 11-deoxycortisol accumulates (and is measured in plasma as a surrogate marker of drug action) while cortisol falls. Metyrapone has high bioavailability (greater than 80%) after oral administration, with peak effect within 2 hours and a plasma half-life of approximately 1.9 hours for the parent compound; the active metabolite metyrapol extends the pharmacodynamic half-life somewhat. Usual dosing is 750 mg to 6 g daily in three to four divided doses, titrated to normalize UFC. Metyrapone does not significantly inhibit androgen synthesis, so the cortisol precursor 11-deoxycortisol that accumulates is not androgenic, but the block proximal to CYP11B2 (aldosterone synthase) reduces mineralocorticoid precursor conversion, which can lead to hypokalemia and hypertension via accumulation of the weak mineralocorticoid 11-deoxycorticosterone (DOC). Additional adverse effects include hirsutism and acne in women (due to accumulation of androgenic precursors above CYP11B1 from adrenocorticotropic hormone (ACTH)-driven adrenocortical stimulation), nausea, dizziness, and headache.1213
Osilodrostat (Isturisa) is a newer, potent oral CYP11B1 inhibitor with additional CYP11B2 (aldosterone synthase) inhibitory activity. It is approved for Cushing disease and produces UFC normalization in approximately 53 to 79% of patients at 12 weeks in phase 3 trials, with a favorable safety profile compared with metyrapone and ketoconazole. Osilodrostat is twice-daily oral dosing starting at 2 mg twice daily, titrated upward by 1 to 2 mg increments based on UFC response. Unlike metyrapone, osilodrostat also inhibits CYP11B2 and thereby reduces aldosterone synthesis in addition to cortisol, which can cause hypotension and hypokalemia via aldosterone deficiency rather than DOC accumulation; electrolyte monitoring (potassium, sodium) and blood pressure assessment are important at each dose titration. The main adverse effects are adrenal insufficiency (if over-treated), fatigue, nausea, headache, and QT prolongation (which is modest at therapeutic doses but requires ECG monitoring). Osilodrostat is metabolized by CYP3A4 and is a moderate inhibitor of CYP2D6 (cytochrome P450 2D6); the CYP2D6 interaction can increase plasma concentrations of CYP2D6-sensitive drugs such as tricyclic antidepressants and certain beta-blockers.13
Mitotane (o,p′-DDD) is an adrenolytic agent derived from the insecticide DDT (dichlorodiphenyltrichloroethane) that produces selective destruction of the adrenal cortex through direct cytotoxic mechanisms (formation of reactive acyl chloride intermediates that alkylate adrenocortical cell proteins) in addition to inhibiting multiple adrenal steroidogenic enzymes including CYP11A1, CYP11B1, CYP11B2, and CYP17A1. Mitotane is indicated primarily for adrenocortical carcinoma (ACC) but is also used in Cushing disease and Cushing syndrome of adrenal origin when other agents have failed. It is administered orally in doses of 2 to 6 g daily in three to four divided doses with fatty food (which substantially increases bioavailability from its highly lipophilic nature). The onset of therapeutic action is slow (weeks to months) owing to high lipid solubility and extensive accumulation in adipose tissue; the effective plasma concentration range is 14 to 20 mg/L and plasma level monitoring is required. Mitotane is a potent inducer of CYP3A4 and CYP2B6 (cytochrome P450 2B6), leading to accelerated metabolism of many drugs including warfarin (requiring dose increases of 50% or more), corticosteroids (requiring higher replacement doses), and oral contraceptives. Because mitotane produces adrenal destruction, all patients on maintenance mitotane require lifelong glucocorticoid and mineralocorticoid replacement therapy. The neurotoxic adverse effects of mitotane at therapeutic plasma concentrations include cerebellar ataxia, cognitive impairment, somnolence, and confusion; these are dose-limiting at higher concentrations.14
Ketoconazole: strong CYP3A4 inhibitor; dramatically increases cyclosporine, tacrolimus, statins, and many others; QT prolongation. Avoid with QT-prolonging drugs. LFTs every 2–4 weeks initially. Osilodrostat: CYP3A4 substrate; moderate CYP2D6 inhibitor (increases TCAs, some beta-blockers). QT monitoring. Metyrapone: limited CYP interactions; monitor for DOC-driven hypertension and hypokalemia; nausea common. Mitotane: potent CYP3A4 and CYP2B6 inducer; warfarin doses must be substantially increased; corticosteroid replacement doses must be doubled or tripled; oral contraceptive efficacy impaired. All steroidogenesis inhibitors: adrenal insufficiency is a shared risk — teach patients stress-dose hydrocortisone protocols and provide injectable hydrocortisone for emergencies.
Mifepristone (Korlym) is a synthetic antiprogestin and glucocorticoid receptor (GR) antagonist approved for the management of hyperglycemia in adults with Cushing syndrome, including Cushing disease, who have failed surgery or are not surgical candidates. It binds the GR (glucocorticoid receptor) with high affinity (approximately three-fold higher than cortisol) and blocks glucocorticoid signaling at target tissues, reducing the metabolic and clinical manifestations of cortisol excess without reducing cortisol secretion itself. Because mifepristone does not lower cortisol production, serum cortisol and adrenocorticotropic hormone (ACTH) levels actually rise during therapy as pituitary and hypothalamic negative feedback is blocked; these biomarkers therefore cannot be used to assess treatment adequacy or monitor for adrenal insufficiency. Clinical endpoints (blood glucose, blood pressure, weight, psychiatric symptoms) are used instead. Mifepristone is also a potent progesterone receptor antagonist, which drives its most limiting adverse effects: endometrial thickening, vaginal bleeding, and endometrial hyperplasia in premenopausal and postmenopausal women on estrogen; these effects require gynecological monitoring and may necessitate drug discontinuation. Mifepristone is extensively metabolized by CYP3A4 (cytochrome P450 3A4); strong CYP3A4 inhibitors substantially increase mifepristone exposure and are contraindicated or require dose reduction.15
Nelson syndrome is the development of an aggressive, invasive ACTH-secreting corticotroph adenoma following bilateral adrenalectomy (BLA) performed for refractory Cushing disease. When the adrenal glands are removed, cortisol production ceases and hypothalamic-pituitary negative feedback is permanently lost, driving sustained and unopposed ACTH hypersecretion from the corticotroph adenoma. Without cortisol feedback, the residual pituitary corticotroph tumor can enlarge rapidly (in some series, a majority of patients with Cushing disease who undergo BLA develop Nelson syndrome), producing mass effects including visual field loss, cavernous sinus invasion, and extremely high ACTH levels (often above 500 pg/mL). Hyperpigmentation from ACTH-driven melanocyte-stimulating hormone activity is a clinical hallmark. Pituitary radiotherapy administered after BLA before Nelson syndrome develops reduces but does not eliminate the risk. Once Nelson syndrome is established, management options include repeat transsphenoidal surgery, radiotherapy (stereotactic radiosurgery or fractionated), temozolomide for aggressive tumors, and medical therapy including pasireotide (which can reduce ACTH in some corticotroph tumors via SSTR5) and cabergoline.16
The monitoring framework for pituitary adenoma pharmacotherapy integrates biochemical, radiological, and safety surveillance. For prolactinoma: serum prolactin every 3 months during cabergoline titration, then every 6 to 12 months once stable; pituitary magnetic resonance imaging (MRI) every 1 to 2 years during active medical therapy (more frequently for macroprolactinomas); gonadal function assessment (testosterone in men, menstrual regularity and estradiol in women); bone mineral density (BMD) by dual-energy X-ray absorptiometry (DEXA) scan, as hyperprolactinemia-driven hypogonadism causes bone loss that reverses with treatment. For Cushing disease pharmacotherapy: urinary free cortisol (UFC) or late-night salivary cortisol (LNSC) every 4 to 6 weeks during dose titration; LFTs every 2 to 4 weeks for ketoconazole; electrolytes (potassium, sodium) and blood pressure for all steroidogenesis inhibitors; HbA1c and fasting glucose for pasireotide; electrocardiogram (ECG) for ketoconazole, osilodrostat; pituitary MRI every 6 to 12 months in active Cushing disease. For acromegaly adjunct therapies: echocardiography at baseline if cumulative cabergoline dose is expected to be substantial; LFTs quarterly for pegvisomant combination. The overarching monitoring principle is that each drug class has both a pharmacodynamic endpoint (the hormone or biomarker being suppressed) and a safety endpoint (organ toxicity or systemic effect), both requiring systematic surveillance.913
Drug interactions across the pituitary adenoma drug pharmacopeia deserve particular attention in patients receiving polypharmacy for multisystem disease. Mifepristone is a strong inhibitor of CYP3A4 at clinical doses, which increases the exposure of numerous drugs; it is also a substrate of CYP3A4, creating the potential for bidirectional interactions. Cabergoline at Cushing disease doses interacts with antipsychotics and metoclopramide (pharmacodynamic antagonism), sympathomimetics (enhanced vasospasm), and macrolide antibiotics or azole antifungals (CYP3A4 inhibition increases cabergoline levels). Osilodrostat, by inhibiting CYP2D6 (cytochrome P450 2D6), can increase plasma levels of codeine-to-morphine conversion (altered analgesia), tricyclic antidepressants (increased anticholinergic and cardiotoxic effects), and metoprolol (enhanced beta-blockade). Mitotane’s CYP3A4 induction requires warfarin anticoagulation monitoring with INR (international normalized ratio) checks every 2 weeks until a new stable dose is achieved; failure to increase warfarin doses risks thromboembolism in a population already at elevated risk from cortisol-driven hypercoagulability.1415
Cortisol and ACTH rise during mifepristone therapy because glucocorticoid receptor blockade eliminates hypothalamic-pituitary negative feedback. A rising cortisol level does not indicate worsening disease or treatment failure; it is the expected pharmacodynamic response. Do not use serum cortisol or UFC to monitor mifepristone efficacy or to diagnose adrenal insufficiency in patients on mifepristone. Use clinical endpoints: glucose control, blood pressure, weight, cushingoid features. For adrenal insufficiency diagnosis on mifepristone: use clinical signs (hypotension, fatigue, hyponatremia) rather than cortisol levels, and treat empirically with high-dose hydrocortisone if adrenal insufficiency is clinically suspected, then discontinue mifepristone to restore normal feedback. Gynaecological monitoring (endometrial ultrasound) is required annually in all women.
Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
doi:10.1210/jc.2010-1692Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265–273.
doi:10.1111/j.1365-2265.2006.02562.xWebster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904–909.
doi:10.1056/NEJM199410063311403Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023–2033.
doi:10.1056/NEJMoa022657Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43–52.
doi:10.1007/s11102-005-5085-2Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–378.
doi:10.1210/jcem.83.2.4556Gadelha MR, Bronstein MD, Brue T, et al; PAOLA study investigators. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884.
doi:10.1016/S2213-8587(14)70169-XHenry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–3453.
doi:10.1210/jc.2013-1771Nieman LK, Biller BMK, Findling JW, et al; Endocrine Society. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–2831.
doi:10.1210/jc.2015-1818Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914–924.
doi:10.1056/NEJMoa1105743Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–230.
doi:10.1210/jc.2008-1533Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–1630.
doi:10.1210/jc.2013-3628Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease. Pituitary. 2016;19(2):138–148.
doi:10.1007/s11102-015-0692-zTerzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372–2380.
doi:10.1056/NEJMoa063360Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–2049.
doi:10.1210/jc.2011-3350Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA. Nelson's syndrome. Eur J Endocrinol. 2010;163(4):495–507.
doi:10.1530/EJE-10-0466